Table 3 Diagnostic performance of anti-CCP2 antibodies and RF in rheumatoid arthritis
Anti-CCP2 | R.A. vs non R.A. | R.A. vs other diseases | R.A. vs blood donors |
|---|---|---|---|
AUC | 0.90 (95% CI: 0.87 – 0.93) | 0.87 (95% CI: 0.83 – 0.91) | 0.95 (95% CI: 0.92 – 0.97) |
Sensitivity* | 63.6% (95% CI: 55.8% – 70.8%) | 63.6% (95% CI: 55.8% – 70.8%) | 63.6% (95% CI: 55.8% – 70.8%) |
Specificity* | 95.0% (95% CI: 91.7% – 97.0%) | 92.1% (95% CI: 87.2% – 95.3%) | 100% (95% CI: 96.4% – 100%) |
PPV* | 87.5% (95% CI: 80.1% – 92.4%) | 87.5% (95% CI: 80.1% – 92.4%) | 100% (95% CI: 96.2% – 100%) |
NPV* | 83.8% (95% CI: 80.0% – 87.0%) | 74.55% (95% CI: 68.4% – 79.8%) | 64.1% (95% CI: 56.3% – 71.2%) |
LR +* | 12.6 (95% CI: 10.9 – 14.7) | 8.1 (95% CI: 6.95 – 9.41) | Undefined |
LR -* | 0.38 (95% CI: 0.37 – 0.40) | 0.39 (95% CI: 0.38 – 0.41) | 0.36 (95% CI: 0.35 – 0.38) |
Diagnostic OR* | 33 (95% CI: 17.6 – 61.9) | 20.5 (95% CI: 10.8 – 38.8) | Undefined |
RF | R.A. vs non R.A. | R.A. vs other diseases | R.A. vs blood donors |
AUC | 0.71 (95% CI: 0.64 – 0.77) | 0.719 (95% CI: 0.66 – 0.78) | 0.682 (95% CI: 0.61 – 0.76) |
Sensitivity* | 59.09% (95% CI: 51.2% – 66.5%) | 59.09% (95% CI: 51.2% – 66.5%) | 59.09% (95% CI: 51.2% – 66.5%) |
Specificity* | 91.24% (95% CI: 87.3% – 94.0%) | 87.93% (95% CI: 82.3% – 92.0%) | 97.00% (95% CI: 91.6% – 99.0%) |
PPV* | 79.13% (95% CI: 70.8% – 85.6%) | 81.25% (95% CI: 73.0% – 87.4%) | 96.81% (95% CI: 91.0% – 98.9%) |
NPV* | 79.87% (95% CI: 75.1% – 83.9%) | 70.83% (95% CI: 64.5% – 76.5%) | 60.62% (95% CI: 52.9% – 67.9%) |
LR +* | 6.75 (95% CI: 6.13 – 7.43) | 4.89 (95% CI: 4.39 – 5.46) | 19.70 (95% CI: 10.10 – 38.43) |
LR -* | 0.45 (95% CI: 0.43 – 0.46) | 0.47 (95% CI: 0.45 – 0.48) | 0.42 (95% CI: 0.41 – 0.44) |
Diagnostic OR* | 15.05 (95% CI: 8.88 – 25.51) | 10.52 (95% CI: 6.02 – 18.38) | 46.70 (95% CI: 14.17 – 154.00) |